Razieh Kebriaei1, Kyle C Stamper1, Kavindra V Singh2,3, Ayesha Khan2,3,4, Seth A Rice1, An Q Dinh2,3, Truc T Tran2,3, Barbara E Murray2,3,4, Cesar A Arias2,3,4,5,6, Michael J Rybak1,7. 1. Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy & Health Sciences, Detroit, Michigan, USA. 2. Division of Infectious Diseases, UTHealth McGovern Medical School, Houston, Texas, USA. 3. Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School, Houston, Texas, USA. 4. Department of Microbiology and Molecular Genetics, UTHealth McGovern Medical School, Houston, Texas, USA. 5. Center for Infectious Diseases, UTHealth School of Public Health, Houston, Texas, USA. 6. Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics; Universidad El Bosque, Bogotá, Colombia. 7. School of Medicine, Wayne State University, Detroit, Michigan, USA.
Abstract
BACKGROUND: The combination of daptomycin (DAP) plus ampicillin (AMP), ertapenem (ERT), or ceftaroline has been demonstrated to be efficacious against a DAP-tolerant Enterococcus faecium strain (HOU503). However, the mechanism for the efficacy of these combinations against DAP-resistant (DAP-R) E. faecium strains is unknown. METHODS: We investigated the efficacy of DAP in combination with AMP, ERT, ceftaroline, ceftriaxone, or amoxicillin against DAP-R E. faecium R497 using established in vitro and in vivo models. We evaluated pbp expression, levels of penicillin-binding protein (PBP) 5 (PBP5) and β-lactam binding affinity in HOU503 versus R497. RESULTS: DAP plus AMP was the only efficacious regimen against DAP-R R497 and prevented emergence of resistance. DAP at 8, 6, and 4 mg/kg in combination with AMP was efficacious but showed delayed killing compared with 10 mg/kg. PBP5 of HOU503 exhibited amino acid substitutions in the penicillin-binding domain relative to R497. No difference in pbp mRNA or PBP5 levels was detected between HOU503 and R497. labeling of PBPs with Bocillin FL, a fluorescent penicillin derivative, showed increased β-lactam binding affinity of PBP5 of HOU503 compared with that of R497. CONCLUSIONS: Only DAP (10 mg/kg) plus AMP or amoxicillin was efficacious against a DAP-R E. faecium strain, and pbp5 alleles may be important contributors to efficacy of DAP plus β-lactam therapy.
BACKGROUND: The combination of daptomycin (DAP) plus ampicillin (AMP), ertapenem (ERT), or ceftaroline has been demonstrated to be efficacious against a DAP-tolerant Enterococcus faecium strain (HOU503). However, the mechanism for the efficacy of these combinations against DAP-resistant (DAP-R) E. faecium strains is unknown. METHODS: We investigated the efficacy of DAP in combination with AMP, ERT, ceftaroline, ceftriaxone, or amoxicillin against DAP-R E. faecium R497 using established in vitro and in vivo models. We evaluated pbp expression, levels of penicillin-binding protein (PBP) 5 (PBP5) and β-lactam binding affinity in HOU503 versus R497. RESULTS: DAP plus AMP was the only efficacious regimen against DAP-R R497 and prevented emergence of resistance. DAP at 8, 6, and 4 mg/kg in combination with AMP was efficacious but showed delayed killing compared with 10 mg/kg. PBP5 of HOU503 exhibited amino acid substitutions in the penicillin-binding domain relative to R497. No difference in pbp mRNA or PBP5 levels was detected between HOU503 and R497. labeling of PBPs with Bocillin FL, a fluorescent penicillin derivative, showed increased β-lactam binding affinity of PBP5 of HOU503 compared with that of R497. CONCLUSIONS: Only DAP (10 mg/kg) plus AMP or amoxicillin was efficacious against a DAP-R E. faecium strain, and pbp5 alleles may be important contributors to efficacy of DAP plus β-lactam therapy.
Authors: L B Rice; L L Carias; R Hutton-Thomas; F Sifaoui; L Gutmann; S D Rudin Journal: Antimicrob Agents Chemother Date: 2001-05 Impact factor: 5.191
Authors: Amy G Prater; Heer H Mehta; Abigael J Kosgei; William R Miller; Truc T Tran; Cesar A Arias; Yousif Shamoo Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Razieh Kebriaei; Seth A Rice; Kavindra V Singh; Kyle C Stamper; An Q Dinh; Rafael Rios; Lorena Diaz; Barbara E Murray; Jose M Munita; Truc T Tran; Cesar A Arias; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191
Authors: Jose M Munita; Truc T Tran; Lorena Diaz; Diana Panesso; Jinnethe Reyes; Barbara E Murray; Cesar A Arias Journal: Antimicrob Agents Chemother Date: 2013-03-18 Impact factor: 5.191
Authors: Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond Journal: Clin Infect Dis Date: 2004-07-15 Impact factor: 9.079
Authors: Romney M Humphries; Theodoros Kelesidis; Ryan Tewhey; Warren E Rose; Nicholas Schork; Victor Nizet; George Sakoulas Journal: Antimicrob Agents Chemother Date: 2012-09-04 Impact factor: 5.938
Authors: Ayesha Khan; Milya Davlieva; Diana Panesso; Sandra Rincon; William R Miller; Lorena Diaz; Jinnethe Reyes; Melissa R Cruz; Orville Pemberton; April H Nguyen; Sara D Siegel; Paul J Planet; Apurva Narechania; Mauricio Latorre; Rafael Rios; Kavindra V Singh; Hung Ton-That; Danielle A Garsin; Truc T Tran; Yousif Shamoo; Cesar A Arias Journal: Proc Natl Acad Sci U S A Date: 2019-12-09 Impact factor: 11.205
Authors: Razieh Kebriaei; Kyle C Stamper; Katherine L Lev; Taylor Morrisette; Jacinda C Abdul-Mutakabbir; Raymond Schuch; Dario Lehoux; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2021-08-16 Impact factor: 5.191
Authors: Taylor Morrisette; Katherine L Lev; Gregory S Canfield; Breck A Duerkop; Razieh Kebriaei; Kyle C Stamper; Dana Holger; Susan M Lehman; Smaranda Willcox; Cesar A Arias; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2021-11-01 Impact factor: 5.938
Authors: Katherine Lev; Ashlan J Kunz Coyne; Razieh Kebriaei; Taylor Morrisette; Kyle Stamper; Dana J Holger; Gregory S Canfield; Breck A Duerkop; Cesar A Arias; Michael J Rybak Journal: Antibiotics (Basel) Date: 2022-03-15